Introduction
============

The reason why we cannot specifically treat experimental autoimmune disorders and naturally occurring autoimmune diseases in humans is that we still do not fully understand the autoimmune events that take place and contribute to the maintenance or loss of tolerance to self ([@b70-btt-1-59]; [@b74-btt-1-59]; [@b69-btt-1-59]; [@b25-btt-1-59]; [@b44-btt-1-59]). Hence autoimmune diseases are still not treated specifically, but rather with immunosuppressive agents. Not only are immunosuppressive agents nonspecific in action, most often resulting in serious side effects, but they also fail to cure the disease, since the underlying pathogenic immune events can continue despite the control of symptoms ([@b16-btt-1-59]; [@b30-btt-1-59]).

It should be acknowledged that not every autoimmune process is harmful. In effect, most of the autoimmune process related events occurring throughout life are physiologic ([@b31-btt-1-59], [@b32-btt-1-59]; [@b73-btt-1-59]; [@b73-btt-1-59]; [@b19-btt-1-59]; [@b49-btt-1-59]; [@b21-btt-1-59]). Physiologic autoimmune events contribute in a major way towards the catabolism of intracytoplazmic components released into the circulation from cells at the end of their life span. In a physiological sense, we are not per se "tolerant" to our intracytoplazmic components ([@b75-btt-1-59]), since specific immunoglobulin M (IgM) autoantibodies (aabs) are designated from birth to react with these components and assist in their removal once they are released into the intravascular space ([@b63-btt-1-59]). Such events prevent toxic accumulation of tissue breakdown products and/or their chemical modification by intrinsic or foreign agents ([@b80-btt-1-59]). Chemically modified autoantigens (aags) can initiate pathogenic autoimmune disease-causing responses ([@b68-btt-1-59]).

The development of an autoimmune disease therefore results in most instances not from some malfunctioning of the immune system against normal self components but from abnormal presentation of self or self-like molecules to the cells of the immune system (ie, as modified self or by molecular mimicry) ([@b12-btt-1-59]; [@b28-btt-1-59]; [@b77-btt-1-59]; [@b39-btt-1-59]; [@b10-btt-1-59]). This thesis presumes that normal intracytoplazmic components will not produce autoimmune disease per se but in the meantime does not preclude their participation in lesion development. The following explanation will help to clarify these statements.

Issues relating to altered self antigen initiated events
========================================================

If a native antigen (ag) from the target organ is exposed and becomes modified, eg, by a chemical agent ([@b58-btt-1-59]; [@b68-btt-1-59]; [@b80-btt-1-59]; [@b56-btt-1-59]) in the intravascular space, or if a modified self-like ag is administered repeatedly ([@b8-btt-1-59], [@b10-btt-1-59]), then the following events can occur:

-   If the modified ag initiated events are short-lived, then a limited pathogenic autoimmune disease process will result in minimal functional and morphological alterations in the target organ ([@b68-btt-1-59]).

-   If the modified ag initiated events are maintained, then a progressive autoimmune disease process will ensue by the developing pathogenic immunoglobulin G (IgG) aabs and cause major morphological and functional change in the target organ resulting in a diagnosable autoimmune disease ([@b35-btt-1-59]; [@b47-btt-1-59]).

Pathogenic autoimmune disease-causing events can take place because the pathogenic aab (resulting from the stimulation of IgG aab producing cell lines by the modified native ag) is able to cross-react with both native and modified aags present in the circulation and in the target organ (eg, in the kidney it reacts with fixed glomerular kidney ags and forms immune complexes (ICs) during the course of the autoimmune disease).

Genetic predisposition can also affect autoimmune disease development. Certain patients are unable to respond with sufficiently strong immune responses to bacterial or viral infections. Under such circumstances, bacterial or viral breakdown products linger on at the site of infection, and sustained tissue damage occurs whereby cells are injured and intracytoplazmic components are released. In this local milieu the ideal conditions are thus created for the modification of self ags. If a low-grade chronic infection persists, then pathogenic IgG aab production (occurring alongside IgM aab production) can commence. If such events are sufficiently prolonged then serious morphologic and functional alterations can take place in the target organ and lead to a chronic progressive autoimmune disease ([@b78-btt-1-59]).

Genetic susceptibility could also be due to physiologic immune response deficiency where an infection is not involved. For example, an individual's immune system might be unable to produce sufficient amounts of specific IgM aabs to clear released intracytoplazmic ags from the intravascular space; under such conditions aags can become modified by agents (chemicals, drugs, toxic compounds, etc) present in the circulation and initiate pathogenic IgG aab response against the modified self. If pathogenic IgG aabs are continuously produced then damage to a target organ can cause a low-grade slowly progressive autoimmune disease.

Issues relating to normal self ag initiated events
==================================================

Although normal aags will not themselves produce an autoimmune disease, they can contribute to disease establishment and progression for two reasons. First, the normal aags within an organ can become the primary targets of pathogenic autoimmune processes ([@b7-btt-1-59]), and second, they can contribute to IC deposits in affected organs (eg, in the glomeruli) ([@b8-btt-1-59]).

In our studies we found that the physiologic IgM aabs and pathogenic IgG aabs cross-react with both normal and modified ags ([@b9-btt-1-59]):

-   Pathogenic aabs reacting with normal aags in the target organ cause autoimmune disease ([@b8-btt-1-59]), and when reacting with modified aags in the circulation, maintain increased pathogenic IgG aab production.

-   Nonpathogenic IgM aabs also react with both native and modified ags in the circulation and assist in their catabolism.

Heightened IgM aab production is maintained alongside IgG aab production during an autoimmune disease state both by native aags per se that are released into the intravascular space ([@b8-btt-1-59]) and by developing ICs (made up of native aags and specific IgM aabs). Thus, while pathogenic IgG aab production attempts to increase the severity of insult against a target, there is a concurrent attempt by the IgM aabs to slow down pathogenic autoimmune processes ([@b11-btt-1-59]).

Despite the normal functioning of the IgM mechanism, as long as the modified ag is present and maintains pathogenic IgG aab production, tissue damage will proceed towards chronic progressive changes that result in morphological and functional alterations. But tipping the balance in favor of increased IgM aab production, in order to neutralize the circulating modified and native ags that contribute to pathogenesis, can halt the autoimmune disease altogether ([@b13-btt-1-59]).

Recent attempts to treat autoimmune disorders
=============================================

So far research scientists have not come up with a specific immune-inducing technique that could prevent or treat endogenous source ag derived chronic ailments (such as autoimmune disorders and cancer). This might be due to the very complex science that describes autoimmune related diseases. Indeed, consensus as to the etiology and pathogenesis of autoimmune diseases still has not been reached ([@b69-btt-1-59]; [@b67-btt-1-59]; [@b29-btt-1-59]; [@b40-btt-1-59]; [@b41-btt-1-59]; [@b59-btt-1-59]; [@b38-btt-1-59]). Consequently, diverse opinions and research efforts continue to contribute to the probative and problem-solving work to find a cure. Under these circumstances the use of immunosuppressive agents is still advocated to treat patients with chronic ailments. In recent years treatment with monoclonal abs has achieved approval but most of such products are not specific in their action and cause side effects. Another treatment modality, the oral presentation of tissue-derived ags, has in experimental animals and even in humans with autoimmune disorders had a degree of beneficial influence on autoimmune disease-causing events, but has not resulted in a cure ([@b54-btt-1-59]; [@b71-btt-1-59], [@b72-btt-1-59]; [@b27-btt-1-59]; [@b17-btt-1-59]).

The form of presentation of the target aag in producing (and also in preventing and treating) an autoimmune disorder can influence outcomes even to the extent of determining final states of disease or no disease. A detailed schematic of the events involved is given in [Figures 1](#f1-btt-1-59){ref-type="fig"} and [2](#f2-btt-1-59){ref-type="fig"}. Under certain circumstances native aags and injected disease-related ags can start or worsen disease progression ([@b50-btt-1-59]), for example when an aag released from the intracytoplazmic environment or an injected disease-related ag is modified by a modifying agent present in the individual's intravascular space ([Figure 3](#f3-btt-1-59){ref-type="fig"}). Such modifying agents can be drugs ([@b80-btt-1-59]) or their metabolic products, or toxic agents derived from infectious microbes etc ([@b33-btt-1-59]). Peptides of microbial proteins, exhibiting sequence similarity or identity to self peptides through molecular mimicry ([@b78-btt-1-59]), can also activate autoreactive T-cells and cause autoimmune disease. Under these unusual circumstances autoimmune disease-initiating processes can take place; however, under normal circumstances "native" intracytoplazmic ags liberated into the circulation will not cause pathogenic IgG aab response.

A new vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease
=========================================================================================================

Heymann nephritis (HN) and slowly progressive Heymann nephritis (SPHN) are pathogenic IgG aab initiated and mediated autoimmune diseases ([@b35-btt-1-59]; [@b10-btt-1-59]). Classical HN is established in susceptible strains of rats by repeated IP injections of nephritogenic ags incorporated into Freund's complete adjuvant \[FCA\] ([@b12-btt-1-59]). After two to four injections of the preparation, progressive proteinuria, severe morphological changes in the kidney, and in the circulation pathogenic IgG aab against the brush-border region of the renal proximal convoluted tubules commences. Attempts to treat HN by various agents before or after the induction of the disease have proved to be unsuccessful ([@b12-btt-1-59], [@b15-btt-1-59]; [@b37-btt-1-59]; [@b20-btt-1-59]; [@b45-btt-1-59]; [@b51-btt-1-59]; [@b79-btt-1-59]; [@b34-btt-1-59];). The futility of these attempts to downregulate immunopathological events has been due to at least two factors:

-   Kidney ag injected in FCA established an irreversibly progressive disease process with the development of pathogenic IgG aabs ([@b2-btt-1-59]).

-   Agents used to circumvent disease development or treat the progressive disease did not act specifically to achieve downregulation or termination of the ab-mediated response against kidney-directed immune insults ([@b12-btt-1-59], [@b15-btt-1-59]; [@b4-btt-1-59]; [@b51-btt-1-59]; [@b34-btt-1-59]; [@b64-btt-1-59]).

We realized that in order to influence immunopathological events we needed to establish a new model of HN that was slowly progressive. We established two models of SPHN. One was produced by using alum instead of FCA as the adjuvant in the injected renal ag ([@b8-btt-1-59]). The other, which perhaps mimics most closely the development of a slowly progressive autoimmune disease in humans, was established by repeated injections of a chemically modified renal ag preparation ([@b10-btt-1-59]). The two SPHN models illustrate the process by which immunological mishaps result in pathogenic autoimmune events that cause harm in target organs and lead to morphological and functional changes.

The next challenge was to find a way to correct such immunological mishaps. To do so we have developed a new vaccination technique, and have successfully employed it in both SPHN models, before and after the initiation of the disease. This modified vaccination technique (MVT), which is a hybrid of active and passive immunization programs, has proven itself capable of redirecting immune responses ([@b9-btt-1-59], [@b6-btt-1-59], [@b11-btt-1-59]).

In our SPHN experimental autoimmune disorder models, the MVT achieved specific downregulation of disease initiating and maintaining events ([Figure 3](#f3-btt-1-59){ref-type="fig"}). We produced specific ICs made up of the disease-causing native kidney tubular ag and specific IgM abs directed against it at slight ag excess ([@b9-btt-1-59], [@b6-btt-1-59], [@b11-btt-1-59]). Injections of these ICs at weekly intervals maintained high levels of circulating nonpathogenic IgM aabs. The increased production of IgM aabs neutralized both modified and native ags by removing them from the circulation and preventing them from playing a part in pathogenic autoimmune events. Since the modified ag was no longer available to stimulate pathogenic IgG aab production, the pathogenic IgG aab producing cell lines were silenced. The unmodified (native) ag, normally located in the glomeruli of the kidney ([@b36-btt-1-59]; [@b23-btt-1-59]) and also present in the circulation ([@b42-btt-1-59]; [@b60-btt-1-59]; [@b61-btt-1-59]), did not remain a target of pathogenic aabs or a contributor to further deposition of IC. The absence of altered or native ags in the circulation meant downregulation of pathogenic autoimmune events ([Figure 3](#f3-btt-1-59){ref-type="fig"}).

We maintain that such downregulation of pathogenic autoimmune events can only be achieved with our MVT. The MVT is effective in both pre- and post-treatment protocols, ie, both in preventing autoimmune disease development ([@b6-btt-1-59]) and in terminating ongoing auto-immune disease processes ([@b9-btt-1-59], [@b11-btt-1-59]). The MVT, via the injection of ICs with predetermined immune inducing components, produces the same class of immunoglobulin (in our case specific IgM aabs directed against the nephritogenic ags both modified and native) with the same specificity against the target ag as resides in the inoculum. The technique provides a specific redirected immune response without influencing normal immune events in any way. The ICs are nontoxic and nonirritant in both short- and long-term applications. The technique achieves total downregulation of pathogenic autoimmune events resulting in regained tolerance. However, since memory cells are retained for pathogenic aab production, pathogenic autoimmune events could start up again if modified ags are reintroduced.

Summary and concluding remarks
==============================

Vaccination over the last 200 years has prevented the occurrence and spread of often lethal infectious and contagious diseases (diphtheria, small pox) in our population. However, in spite of vaccination's development, many diseases initiated and maintained by exogenous ags (HIV/AIDS, malaria, TB) and all of those caused by endogenous ags (autoimmune diseases, cancer) are still not controlled or treated either by prophylactic or therapeutic vaccination programs. Numerous attempts, especially within the last few years, attest to the desire to come up with effective vaccinations to deal with chronic ailments ([@b50-btt-1-59]; [@b57-btt-1-59]; [@b1-btt-1-59]; [@b55-btt-1-59]; [@b62-btt-1-59]; [@b66-btt-1-59]). The fact that we still have not come up with specific vaccination technologies, despite enormous investments of money, manpower, government resources, etc, confirms that the search for a cure is not easy. However, we are inching towards solutions. Lately there have been many publications that provide hope, not only for better drugs, but also for other treatment methods able to influence immune response outcomes ([@b50-btt-1-59]; [@b65-btt-1-59]; [@b43-btt-1-59]; [@b46-btt-1-59]; [@b48-btt-1-59]; [@b22-btt-1-59]; [@b53-btt-1-59]). We have substantial evidence demonstrating that a normally functioning immune system can exert protective immune responses against exogenous source ags (bacteria, viruses, etc) but often not so protective immune responses against harmful endogenous source ags. Sorting out physiologic and pathogenic immune activity against endogenous source ags -- ie, events that can maintain, break, or reestablish tolerance -- would provide us the chance to understand how to manipulate immune responses, eg, for tolerance reestablishment in an autoimmune disease. (In cancer, we would require the opposite. We would want a specific immune response against cells bearing cancer-specific ags, for the elimination of these cancer cells from the host's internal environment).

So far autoimmune diseases have been generally treated with immunosuppressive agents ([@b12-btt-1-59], [@b15-btt-1-59]; [@b18-btt-1-59]; [@b20-btt-1-59]). These medications nonspecifically suppress immune functions and predispose patients to infections. The aim in the last few years has been to find better solutions or techniques to downregulate autoimmune disease-causing immune events. By observing the "natural" and "pathogenic" events that take place in normal and experimental autoimmune disease induced animals, one can investigate physiologic and pathogenic autoimmune responses in health and in disease. Extensive literature documents how aags released from the intracellular environment are assisted in their removal by specific IgM aabs ([@b76-btt-1-59]; [@b26-btt-1-59]; [@b19-btt-1-59]; [@b3-btt-1-59]; [@b21-btt-1-59]; [@b24-btt-1-59]; [@b8-btt-1-59]). These aabs are physiologic and specific in their action against native and corresponding modified native aags. Weir and associates have shown that specific naturally occurring IgM aabs play a significant role in the catabolism of intracytoplazmic ags released from normal cells ([@b52-btt-1-59]; [@b73-btt-1-59]) at the end of their lifespan and following injury by cytotoxic and infectious agents, burns, hypoxia, trauma, etc. Such observations led naturally to the suggestion that these aabs played a role in the maintenance of tolerance to self ags ([@b75-btt-1-59]), ie, by efficiently removing intracytoplazmic waste.

Several experiments have revealed promptly increased IgM aab production (since animals/humans are not per se "tolerant" to escaped intracytoplazmic cell components) following massive release of aags from the intracellular environment \[secondary ab response\] ([@b52-btt-1-59]; [@b73-btt-1-59]; [@b8-btt-1-59]). The elevated level of circulating IgM aabs assist in the removal of released aags. However, if the circulating released aags are not efficiently cleared in the shortest possible time, they can become modified by agents present in the circulation such as drugs or their breakdown products, toxic agents, etc. In order to prevent toxic or modified-self aag accumulation in the intravascular space, we can increase IgM aab production more effectively (ie, not relying on IgM aab stimulation by released aags alone) by administering ICs made up of aags and specific IgM abs directed against them at slight ag excess. These ICs, as mentioned above, will enhance the production of the same class of immunoglobulin with the same specificity against the target ag as resides in the inoculum.

The implementation of our MVT is most appropriate during a pathogenic autoimmune event, such as in our experimental autoimmune kidney disease ([@b9-btt-1-59], [@b5-btt-1-59], [@b6-btt-1-59], [@b11-btt-1-59]), for the following reasons:

-   During an autoimmune disease process both pathogenic IgG aabs and nonpathogenic IgM aabs are produced. Pathogenic aabs cause harm and nonpathogenic aabs attempt to remove both native and modified self ags thereby aiming to terminate autoimmune disease-causing events.

-   The pathogenic IgG aab production is maintained by modified self-like ags.

-   The nonpathogenic IgM aab production is maintained by native aags.

-   Tipping the balance between IgG aab and nonpathogenic IgM aab production in favor of IgM aab response is achieved by injections of suitably assembled ICs made up of the target ag and specific IgM ab against it. The resulting increase in IgM aab in the circulation assists in the removal of both native and modified ags and prevents further production of pathogenic IgG aabs.

-   In certain autoimmune diseases the inciting agent also has to be removed to achieve termination of pathogenic aab production.

We have shown that by redirecting an immune response we can prevent an experimental autoimmune kidney disease-causing process from beginning ([@b6-btt-1-59]) and also terminate it with equal effectiveness when the disease is established ([@b9-btt-1-59], [@b11-btt-1-59]). This solution is achieved by the MVT that we have developed. The vaccination technique can evoke a specific predetermined immune response of our choosing by stimulating appropriate ab-producing cell lines, as long as the appropriate vaccine components are present. The injected components are nontoxic and nonirritant and do not cause any disturbance in the normal functioning of the immune system. The MVT achieves by ab information transfer the production in the vaccinated recipients of the same class of immunoglobulin (ie, ab) with the same specificity against the target ag as resides in the inoculum. According to our assessment, the immune system should be able to correct any mishaps that might occur (associated, eg, with autoimmune diseases, cancer, chronic infections, etc) provided the cells of the immune system are afforded the right presentation of the offending ag.

We predict that this MVT will in time be the vaccination technique of choice for both the prevention and with equal effectiveness the treatment of most of the presently untreatable diseases caused by exogenous and endogenous source ags.

We acknowledge the assistance of our research assistant, Zoltan B Kovacs, in computer-related work.

![Autoimmune processes initiated and maintained by native and modified autologous antigens.\
**Note:** Autoimmune disease is initiated by pathogenic IgG aabs against modified self (or by molecular mimicry). The cells of the individual's immune system see the modified self or self-like ags as exogenous (foreign-like) ags and respond accordingly to eliminate them with the developing IgG aabs. In the process of eliminating a particular aag major damage can occur by the pathogenic IgG aabs reacting with antigenic components in the target organ resulting in organ failure (brought about by morphological and functional changes) and even death. In order to reverse pathogenic autoimmune disease-causing events the following must take place:\
Removal of the inciting agent that modifies the autologous ags, if it can be identified (it could be a drug, infectious agent etc);Increase in the specific IgM aab response against the target ags capable of removing both modified and native ags from the circulation; orPreferably both 1 & 2.\
"Native" aags initiate and maintain physiologic IgM aab response throughout life, assisting in the removal of intracytoplasmic aags released into the intravascular space.\
**Abbreviations:** aab, autoantibody; aag, autoantigen; ag, antigen; AID, autoimmune disease; C, complement; IC, immune complex; IgG, immunoglobulin G; IgM, immunoglobulin M; MW, molecular weight.](btt-1-59f1){#f1-btt-1-59}

![Possible fate of released autoantigens.\
**Note:** Most of the time intracytoplazmic components released from damaged cells will be catabolized by physiological processes involving specific IgM aabs. However, when aags are altered, modified aags can initiate and maintain disease-causing pathogenic aab production.\
**Abbreviations:** aab, autoantibody; aag, autoantigen; IC, immune complex; IgG, immunoglobulin G; IgM, immunoglobulin M; MW, molecular weight.](btt-1-59f2){#f2-btt-1-59}

![Downregulation/upregulation of nonpathogenic and pathogenic autoimmune processes.\
**Note:** Both physiologic and pathogenic autoimmune initiated and maintained events are regulated by the presentation of native and altered self-aags to the cells of the immune system. As shown, autoimmune disease-causing events can be accelerated as well as terminated by appropriate presentation of native aags.\
**Abbreviations:** aab, autoantibody; ag, antigen; IC, immune complex; IgG, immunoglobulin G; IgM, immunoglobulin M; MW, molecular weight.](btt-1-59f3){#f3-btt-1-59}
